HUTCHMED to Present Clinical Data at ESMO Congress and World Lung Cancer Conference 2024

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 – HUTCHMED (China) Limited announced that new and updated findings from several of its clinical studies will be presented at two upcoming medical conferences: the 2024 World Conference on Lung Cancer (WCLC24) in San Diego, USA, and the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

Key findings from the FLOWERS study, a Phase II clinical trial examining osimertinib with or without savolitinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations and MET aberrations, will be showcased at WCLC24. By May 28, 2024, the median follow-up was 8.2 months. Patients in the osimertinib plus savolitinib group (Cohort 2, N=21) displayed a more profound and sustained response compared to the osimertinib monotherapy group (Cohort 1, N=23). The objective response rate (ORR) was 90.5% in Cohort 2 versus 60.9% in Cohort 1, with disease control rates (DCR) of 95.2% and 87%, respectively. The immature progression-free survival (PFS) data suggested a favorable trend for the combination therapy, with median PFS reported at 19.6 months for Cohort 2 compared to 9.3 months for Cohort 1. Both treatment regimens were found to be tolerable and manageable.

Additionally, more data from HUTCHMED’s research will be presented at ESMO Congress 2024. These include further analyses of the FRESCO-2 and FRUTIGA studies, focused on metastatic colorectal cancer and gastric cancer, respectively, along with a biomarker study of savolitinib in gastric cancer. Investigator-led studies involving fruquintinib and surufatinib will also be detailed.

At WCLC24, the following abstracts will be presented:
1. "Osimertinib with or without savolitinib as 1L in de novo MET aberrant, EGFRm advanced NSCLC (CTONG 2008): A Phase II trial" by Jinji Yang from Guangdong Lung Cancer Institute will be part of the Plenary Session on Monday, September 9, 2024.
2. "Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC" by Yingying Du and Hesheng Qian.
3. "Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study" by Qitao Yu and Wei Jiang.

At ESMO 2024, the presentations will include:
1. "Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase 3 FRESCO-2 trial" by Rocio Garcia-Carbonero.
2. "Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age" by Maria Elena Elez Fernandez.
3. "Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients with prior immunotherapy: Subgroup analysis from FRUTIGA study" by Lin Shen.

Other notable presentations include:
- "Impact of subsequent anti-tumor therapies in patients with advanced gastric or gastroesophageal junction adenocarcinoma receiving fruquintinib plus paclitaxel or placebo plus paclitaxel" by Ruihua Xu.
- "Association between Fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a Phase 3 study of Fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction adenocarcinoma" by Shukui Qin.

HUTCHMED is a biopharmaceutical company dedicated to developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It has a workforce of approximately 5,000 employees, including around 1,800 in oncology/immunology. The company’s mission is to bring innovative cancer treatments discovered in-house to patients worldwide, with its first three medicines already marketed in China and the first of them also available in the US and Europe.